Skip to main content
Fig. 5 | Stem Cell Research & Therapy

Fig. 5

From: A novel MSC-based immune induction strategy for ABO-incompatible liver transplantation: a phase I/II randomized, open-label, controlled trial

Fig. 5

Sixth-month graft biopsies. Representative sections of the livers stained with CK19, including cases of no biliary complications and cases of ITBL during MSCs or rituximab treatment (× 200 magnification). a No biliary complications occurred in the MSC group, and the bile ducts stained with CK19 were normal. b CK19 staining of patients with or without biliary complications in the rituximab group. Abnormal changes included dilation and atresia of the bile ducts with ITBL

Back to article page

Stem Cell Research & Therapy

ISSN: 1757-6512